R. Loomba

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

BACKGROUND & AIMS Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis. APPROACH AND RESULTS Adults with biopsy-pro...

Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.

BACKGROUND AND AIMS The American Association for the Study of Liver Diseases (AASLD) recommends that a decline in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) can be used as a non-invasive endpoint for treatment response in metabolic dysfunction-associated steatohepatitis (MAS...

Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.

Gut microbiome and metabolite profiles are associated with subsequent histologic MASH in a longitudinal mouse model

ABSTRACT Detecting metabolic dysfunction-associated steatohepatitis (MASH) before fibrosis develops remains a major challenge. We used a longitudinal streptozotocin/high-fat diet (STAM/HFD) mouse model to identify microbial and metabolic features that emerge before histological MASH onset. Integrative 16S rRNA and unta...

Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.

Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.